Key Drivers
- Liquidity Strength
- Revenue Shortfall
- Cash Burn
AIAI Summary
ABSI should now be viewed less as a broad platform story and more as a concentrated bet on ABS-201, because its cash runway into 1H28 buys time but not conviction—investors need clear, differentiated human efficacy and safety data quickly, or the narrowed pipeline, ongoing burn, and dilution risk will keep the stock fragile.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Revenue Shortfall
- •Cash Burn
ABSI has strong liquidity and very low leverage, but tiny revenue, persistent large losses, negative cash flow, and a demanding valuation make it a high-risk stock. క
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Momentum fading
- •Support holding
ABSI remains in a constructive last month uptrend above its late-April base, but the 14% pullback from the recent $5.95 peak and slip below $5.30-$5.36 signal fading near-term momentum.
About a 14% drop from the
Sentiment & News
Key News Insights:
- •ABS-201 progress
- •Q1 revenue miss
- •MAD dosing start
Absci's ABS-201 program showed encouraging clinical progress with all planned healthy-volunteer SAD cohorts dosed and MAD dosing underway, but its Q1 2026 results missed estimates with a loss and weaker revenue.
The clinical update is a positive de-risking signal, but the weaker quarterly financials may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings